GeneDx (WGS) to Release Earnings on Monday

GeneDx (NASDAQ:WGS) is anticipated to release its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect GeneDx to post earnings of ($0.06) per share and revenue of $112.4560 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $120.99 million for the quarter, compared to analysts’ expectations of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Stock Up 4.0%

WGS opened at $65.38 on Friday. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. GeneDx has a 52 week low of $55.17 and a 52 week high of $170.87. The stock has a market cap of $1.91 billion, a PE ratio of -87.17 and a beta of 2.06. The business’s fifty day simple moving average is $71.45 and its 200 day simple moving average is $107.27.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research report on Monday, February 23rd. Guggenheim cut their target price on shares of GeneDx from $170.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Wells Fargo & Company raised shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price for the company in a research report on Monday, February 9th. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.17.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 392 shares of the business’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total transaction of $25,554.48. Following the completion of the sale, the chief financial officer owned 34,942 shares of the company’s stock, valued at $2,277,868.98. The trade was a 1.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister acquired 140,026 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were acquired at an average cost of $81.19 per share, with a total value of $11,368,710.94. Following the transaction, the director owned 3,228,150 shares in the company, valued at approximately $262,093,498.50. This trade represents a 4.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders sold 113,402 shares of company stock worth $8,227,718. 29.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of WGS. Franklin Resources Inc. lifted its stake in shares of GeneDx by 101.9% during the 3rd quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock valued at $73,412,000 after buying an additional 343,954 shares in the last quarter. Invesco Ltd. lifted its stake in GeneDx by 59.2% in the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in GeneDx by 717.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 258,745 shares of the company’s stock worth $33,652,000 after purchasing an additional 227,088 shares in the last quarter. ARK Investment Management LLC raised its position in shares of GeneDx by 35.3% during the 4th quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock valued at $78,629,000 after buying an additional 157,582 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of GeneDx by 76.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 255,931 shares of the company’s stock valued at $23,625,000 after buying an additional 110,684 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.